Physician profile
David Dpm Mai
NPI 1972826808
$179,572.69
in general payments reported to CMS, 2019-2025
24 companies · $4,574 in 2025
The $4,574 reported for 2025 was more than what 93% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $477 · 2021: $17K · 2022: $77K · 2023: $29K · 2024: $24K · 2025: $4,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $6,921 · Food and Beverage: $2,970 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,681.25 |
| Travel and Lodging | $6,920.51 |
| Food and Beverage | $2,969.69 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145,041.77 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $23,602.26 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $4,322.16 | 2019-2022 | |
| Horizon Therapeutics Plc | $3,333.76 | 2019-2020 | |
| Hnm Stainless, LLC | $1,123.33 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $350.00 | 2023 | Veregen |
| Hnm Total Recon | $338.31 | 2021 | |
| Organogenesis INC. | $309.62 | 2021-2025 | Apligraf, Puraply Wound Matrix, Puraply |
| Kowa Pharmaceuticals America, INC. | $228.08 | 2022-2023 | Seglentis |
| Melinta Therapeutics, LLC | $198.22 | 2019-2022 | |
| Flower Orthopedics Coporation | $132.10 | 2019 | |
| Stryker Corporation | $116.36 | 2025 | Alphavent |
| Embody, INC. | $81.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $63.08 | 2024-2025 | |
| Treace Medical Concepts, INC. | $61.72 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $60.26 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $51.63 | 2022-2025 | Nuzyra |
| Allergan, INC. | $28.90 | 2020 | |
| Depuy Synthes Sales INC. | $25.48 | 2024 | |
| Ermi LLC | $23.91 | 2025 | |
| Integra Lifesciences Corporation | $22.56 | 2020 | |
| Djo, LLC | $21.88 | 2025 | Cmf |
| Smith+Nephew, INC. | $20.00 | 2024 | Collagenase Santyl |
| Baudax Bio INC. | $16.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.